Austar Lifesciences (HKSE:06118) Long-Term Capital Lease Obligation : HK$57 Mil (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Austar Lifesciences Long-Term Capital Lease Obligation?

Austar Lifesciences's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$57 Mil.

Austar Lifesciences's quarterly Long-Term Capital Lease Obligation declined from Dec. 2022 (HK$70 Mil) to Jun. 2023 (HK$60 Mil) and declined from Jun. 2023 (HK$60 Mil) to Dec. 2023 (HK$57 Mil).

Austar Lifesciences's annual Long-Term Capital Lease Obligation increased from Dec. 2021 (HK$43 Mil) to Dec. 2022 (HK$70 Mil) but then declined from Dec. 2022 (HK$70 Mil) to Dec. 2023 (HK$57 Mil).

Austar Lifesciences Long-Term Capital Lease Obligation Historical Data

The historical data trend for Austar Lifesciences's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Austar Lifesciences Long-Term Capital Lease Obligation Chart

Austar Lifesciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

27.81

38.33

42.72

70.21

57.03

Austar Lifesciences Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															42.72	40.11	70.21	59.65	57.03

Austar Lifesciences (HKSE:06118) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Austar Lifesciences Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Austar Lifesciences's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Austar Lifesciences (HKSE:06118) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Austar Lifesciences Ltd (HKSE:06118) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

AULSF:USA

Address

No. 1018, Changning Road, Rooms 2010-2013, 20th Floor, Changning District, Shanghai, CHN

Website

https://www.austar.com.hk

Austar Lifesciences Ltd is a China-based company engaged in providing engineering solutions to pharmaceutical manufacturers and research institutes. The business activity of the group is operated through Liquid and Bioprocess Systems; Clean Room and Automation Control and Monitoring Systems; Powder and Solid Systems; Good Manufacturing Practice (GMP) Compliance Service; Life Science Consumables; and Distribution and Agency of Pharmaceutical Equipment segments. It derives the majority of revenue from the Liquid and Bioprocess System segment which is involved in providing solutions in pharmaceutical and water systems to treat water. The geographical business presence of the firm is seen across China and in other countries.

Austar Lifesciences (HKSE:06118) Headlines

No Headlines